A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
Matthew HummelTjerk BosjeAndrew ShawMark Shiyao LiuAbhijit BarveMudgal KothekarMark A SocinskiCornelius F WallerPublished in: Journal of cancer research and clinical oncology (2021)
MYL-1402O was well tolerated and demonstrated pharmacokinetic and safety profiles similar to EU-reference bevacizumab and US-reference bevacizumab in healthy male volunteers. No new significant safety issues emerged (ClinicalTrials.gov, NCT02469987; ClinicalTrialsRegister.eu EudraCT, 2014-005621-12; June 12, 2015).
Keyphrases